The Trypanocidal Drug Suramin and Other Trypan Blue Mimetics Are Inhibitors of Pyruvate Kinases and Bind to the Adenosine Site*

Ehrlich's pioneering chemotherapeutic experiments published in 1904 (Ehrlich, P., and Shiga, K. (1904) Berlin Klin. Wochenschrift 20, 329–362) described the efficacy of a series of dye molecules including trypan blue and trypan red to eliminate trypanosome infections in mice. The molecular structures of the dyes provided a starting point for the synthesis of suramin, which was developed and used as a trypanocidal drug in 1916 and is still in clinical use. Despite the biological importance of these dye-like molecules, the mode of action on trypanosomes has remained elusive. Here we present crystal structures of suramin and three related dyes in complex with pyruvate kinases from Leishmania mexicana or from Trypanosoma cruzi. The phenyl sulfonate groups of all four molecules (suramin, Ponceau S, acid blue 80, and benzothiazole-2,5-disulfonic acid) bind in the position of ADP/ATP at the active sites of the pyruvate kinases (PYKs). The binding positions in the two different trypanosomatid PYKs are nearly identical. We show that suramin competitively inhibits PYKs from humans (muscle, tumor, and liver isoenzymes, Ki = 1.1–17 μm), T. cruzi (Ki = 108 μm), and L. mexicana (Ki = 116 μm), all of which have similar active sites. Synergistic effects were observed when examining suramin inhibition in the presence of an allosteric effector molecule, whereby IC50 values decreased up to 2-fold for both trypanosomatid and human PYKs. These kinetic and structural analyses provide insight into the promiscuous inhibition observed for suramin and into the mode of action of the dye-like molecules used in Ehrlich's original experiments.

[1]  Kun-Yi Hsin,et al.  EDULISS: a small-molecule database with data-mining and pharmacophore searching capabilities , 2010, Nucleic Acids Res..

[2]  Noel Southall,et al.  Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. , 2010, Bioorganic & medicinal chemistry letters.

[3]  Kun-Yi Hsin,et al.  An improved strategy for the crystallization of Leishmania mexicana pyruvate kinase. , 2010, Acta crystallographica. Section F, Structural biology and crystallization communications.

[4]  Christopher P Austin,et al.  Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. , 2010, Journal of medicinal chemistry.

[5]  M. Walkinshaw,et al.  Allosteric Mechanism of Pyruvate Kinase from Leishmania mexicana Uses a Rock and Lock Model* , 2010, The Journal of Biological Chemistry.

[6]  E. Clercq Antiviral drug discovery: ten more compounds, and ten more stories (part B). , 2009 .

[7]  Regina Z. Cer,et al.  IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding , 2009, Nucleic Acids Res..

[8]  M. Walkinshaw,et al.  Sulphate removal induces a major conformational change in Leishmania mexicana pyruvate kinase in the crystalline state. , 2008, Journal of molecular biology.

[9]  R. McGeary,et al.  Suramin: clinical uses and structure-activity relationships. , 2008, Mini reviews in medicinal chemistry.

[10]  T. Souto-Padrón,et al.  Effect of suramin on the human pathogen Candida albicans: implications on the fungal development and virulence. , 2007, FEMS Immunology & Medical Microbiology.

[11]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[12]  A. Jagielski,et al.  Suramin-induced reciprocal changes in glucose and lactate synthesis in renal tubules contribute to its hyperglycaemic action. , 2006, European journal of pharmacology.

[13]  Barbara M. Bakker,et al.  Experimental and in Silico Analyses of Glycolytic Flux Control in Bloodstream Form Trypanosoma brucei* , 2005, Journal of Biological Chemistry.

[14]  A. Mesecar,et al.  Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. , 2005, Biochemistry.

[15]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[16]  Zefeng Wang,et al.  The Adenosine Analog Tubercidin Inhibits Glycolysis in Trypanosoma brucei as Revealed by an RNA Interference Library* , 2003, Journal of Biological Chemistry.

[17]  Peter Briggs,et al.  A graphical user interface to the CCP4 program suite. , 2003, Acta crystallographica. Section D, Biological crystallography.

[18]  Eugene Krissinel,et al.  The CCP4 molecular-graphics project. , 2002, Acta crystallographica. Section D, Biological crystallography.

[19]  Mark C. Field,et al.  Evidence for a non-LDL-mediated entry route for the trypanocidal drug suramin in Trypanosoma brucei. , 2002, Molecular and biochemical parasitology.

[20]  Laurent R. Chiarelli,et al.  Structure and Function of Human Erythrocyte Pyruvate Kinase , 2002, The Journal of Biological Chemistry.

[21]  Daniel J Rigden,et al.  The putative effector‐binding site of Leishmania mexicana pyruvate kinase studied by site‐directed mutagenesis , 2002, FEBS letters.

[22]  I Lundström,et al.  Suramin blocks nucleotide triphosphate binding to ribosomal protein L3 from Trypanoplasma borreli. , 2000, European journal of biochemistry.

[23]  S. Phillips,et al.  The structure of pyruvate kinase from Leishmania mexicana reveals details of the allosteric transition and unusual effector specificity. , 1999, Journal of Molecular Biology.

[24]  J. Suko,et al.  Suramin and suramin analogs activate skeletal muscle ryanodine receptor via a calmodulin binding site. , 1999, Molecular pharmacology.

[25]  G. H. Reed,et al.  Structure of the bis(Mg2+)-ATP-oxalate complex of the rabbit muscle pyruvate kinase at 2.1 A resolution: ATP binding over a barrel. , 1998, Biochemistry.

[26]  S. S. Huang,et al.  Suramin enters and accumulates in low pH intracellular compartments of v‐sis‐transformed NIH 3T3 cells , 1997, FEBS letters.

[27]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[28]  A. IJzerman,et al.  Suramin analogues as subtype-selective G protein inhibitors. , 1996, Molecular pharmacology.

[29]  F. Opperdoes,et al.  Pyruvate kinase of Leishmania mexicana mexicana. Cloning and analysis of the gene, overexpression in Escherichia coli and characterization of the enzyme. , 1994, Molecular and biochemical parasitology.

[30]  F. Opperdoes,et al.  Synthesis and activity of inhibitors highly specific for the glycolytic enzymes from Trypanosoma brucei. , 1993, Molecular and biochemical parasitology.

[31]  J. Wilting,et al.  Recent research on the biological activity of suramin. , 1993, Pharmacological reviews.

[32]  E. Weinberger,et al.  A pilot study of suramin in the treatment of progressive refractory follicular lymphomas. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  M. Willingham,et al.  In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1,6-bisphosphate. , 1991, The Journal of biological chemistry.

[34]  R. Danesi,et al.  Suramin, a novel antitumor compound , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[35]  K. Huang,et al.  Effects of suramin, an anti-human immunodeficiency virus reverse transcriptase agent, on protein kinase C. Differential activation and inhibition of protein kinase C isozymes. , 1990, The Journal of biological chemistry.

[36]  F. Opperdoes,et al.  Effects of various metabolic conditions and of the trivalent arsenical melarsen oxide on the intracellular levels of fructose 2,6-bisphosphate and of glycolytic intermediates in Trypanosoma brucei. , 1987, European journal of biochemistry.

[37]  F. Opperdoes,et al.  The phosphoglycerate kinases from Trypanosoma brucei. A comparison of the glycosomal and the cytosolic isoenzymes and their sensitivity towards suramin. , 1987, European journal of biochemistry.

[38]  S. Matsushita,et al.  Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. , 1984, Science.

[39]  H A Krebs,et al.  Cytosolic phosphorylation potential. , 1979, The Journal of biological chemistry.

[40]  P. Zuurendonk,et al.  Intramitochondrial and extramitochondrial concentrations of adenine nucleotides and inorganic phosphate in isolated hepatocytes from fasted rats. , 1978, European journal of biochemistry.

[41]  P. Evans,et al.  Scaling and assessment of data quality. , 2006, Acta crystallographica. Section D, Biological crystallography.

[42]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[43]  J. Fantini,et al.  Suramin : a molecule with a broad spectrum of biological and therapeutic properties , 1997 .

[44]  E. Eigenbrodt,et al.  Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. , 1992, Critical reviews in oncogenesis.

[45]  F. Opperdoes Compartmentation of carbohydrate metabolism in trypanosomes. , 1987, Annual review of microbiology.

[46]  S. Subramanian,et al.  Dye-ligand affinity chromatography: the interaction of Cibacron Blue F3GA with proteins and enzymes. , 1984, CRC critical reviews in biochemistry.

[47]  A. Fairlamb,et al.  Uptake of the trypanocidal drug suramin by bloodstream forms of Trypanosoma brucei and its effect on respiration and growth rate in vivo. , 1980, Molecular and biochemical parasitology.

[48]  F. Hawking Suramin: with special reference to onchocerciasis. , 1978, Advances in pharmacology and chemotherapy.

[49]  W. Fischer,et al.  Report on the Use of " Bayer 205 " in Africa. , 1922 .